Table 4.
Univariate and multivariate analysis of pathological tumor size, node status, post-treatment Ki67, post-treatment ER and pre treatment aromatase statusa
| A | ||||||
|---|---|---|---|---|---|---|
| Factor definitions | No. of patients in each group | No. of events/No. of patients | Relapse-free survival | |||
| Univariable analysis | Multivariate analysis | |||||
| HR (95% CI) | P | HR (95% CI) | P | |||
| Tumor sizea (T1/2 vs. T3/4) |
138/33 | 47/171 | 2.7 (1.4–5.0) | 0.002 | 2.82 (1.36–5.85) | 0.006 |
| Node status (Yes vs. No) |
90/69 | 44/159 | 3.9 (1.8–8.4) | 0.0005 | 3.44 (1.58–7.48) | 0.002 |
| Ki67 level, per 2.7 fold increaseb | 48/174 | 1.4 (1.2–1.6) | 0.0002 | 1.1 (1.02–1.09) | 0.003 | |
| ER Allredc (0.2 vs. 3–8) |
16/157 | 48/173 | 2.4 (1.0–5.3) | 0.04 | 2.74 (1.1–6.67) | 0.03 |
| Aromatase statusd (not present versus present) |
37/132 | 48/169 | 1.88 (1.01–3.47) | 0.04 | 2.34 (1.2–4.58) | 0.01 |
| B | ||||||
|---|---|---|---|---|---|---|
| Factor definitions | No. of patients in each group | No. of events/No. of patients | Breast cancer-specific survival | |||
| Univariable analysis | Multivariate analysis | |||||
| HR (95% CI) | P | HR (95% CI) | P | |||
| Tumor size (T1/2 vs. T3/4) |
138/33 | 24/171 | 3.5 (1.5–8.3) | 0.004 | 3.42 (1.21–9.66) | 0.02 |
| Node status (Yes vs. No) |
90/69 | 22/159 | 4.6 (1.4–15.8) | 0.01 | 4.05 (1.14–14.38) | 0.03 |
| Ki67 level, per 2.7 fold increase | 25/174 | 1.4 (1.1–1.7) | 0.009 | 1.05 (1.0–1.11) | 0.06 | |
| ER Allred (0.2 vs. 3–8) |
16/157 | 25/173 | 4.3 (1.6–11.7) | 0.005 | 7.98 (2.58–24.7) | 0.0003 |
| Aromatase status (not present versus present) |
37/132 | 24/169 | 2.82 (1.2–6.63) | 0.02 | 3.76 (1.42–9.98) | 0.008 |
aThe four elements of the preoperative endocrine relapse index (PEPI) score (pathological T and N stage, surgical specimen ER and Ki67 status has been previously described [14]
bSurgical specimen Ki67 was analyzed as the natural log interval, or per 2.7 fold increase according to the original scale of percentage values [14]
cThe ER analysis refers to the post-treatment values, before treatment all the tumors in this data set were ER positive. In the PEPI model, an Allred cut off of 0 or 2 is used to define ER negative
dThe aromatase expression status was defined as present or positive if any positive staining presented in invasive breast cancer cells. Table 4A and B shows the RFS data and BCSS data, respectively